Get Connected:


Latest News

Trending News Today: ACA Repeal on Backburner as Midterm Elections Loom
Top news of the day from across the health care landscape.
Annual meeting explores how to overcome the challenges with patient care that community oncology practices face on a daily basis.
Humana has designed a new value-based care maternity bundled payment model to improve quality, outcomes, and cost across the entire perinatal episode of care for commercial group members with low- to moderate-risk pregnancies. 
Top news of the day from across the health care landscape.
A landmark trial comparing triple therapy fluticasone furoate/umeclidinium/vilaterol (FF/UMEC/VI [Trelegy Ellipta]) versus FF/VI (Relvar; Breo) or FF/UMEC (Anoro) found the former is markedly better in reducing annual rate of on-treatment of moderate/severe exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the clinical effectiveness and economic value of calcitonin gene-related peptide (CGRP) inhibitors for the treatment of chronic or episodic migraines.
Top news of the week from The American Journal of Pharmacy Benefits.
Top news of the day from across the health care landscape.
View More >

From the Journals

New proposed rules for the Medicare Part D drug program could affect the manner in which pharmacy benefit managers administer the program and could impact profitability.
Healthcare stakeholders must evaluate how to use resources more efficiently as it has become clear that driving down prices in one segment of care has not improved medical outcomes for the majority of patients.
This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
An estimation and comparison of the cost of home phototherapy versus biologics over a 3-year time horizon in patients with moderate-to-severe plaque psoriasis.
The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
Buprenorphine treatment with and without induction was found to decrease costs and utilization in opioid-dependent benefciaries.
Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
Upcoming Partner Events